Al-Marzouki, Sanaa; Evans, Stephen; Marshall, Tom; Roberts, Ian (2005): Are these data real? Statistical methods for the detection of data fabrication in clinical trials. In: BMJ (Clinical research ed.) 331 (7511), S. 267–270. DOI: 10.1136/bmj.331.7511.267.
Ansmann E.B, Hecht A, Henn D.K, Leptien S, Stelzer HG. The future of monitoring in clinical research – a holistic approach: Linking risk-based monitoring with quality management principles. GMS German Medical Science 2013; 11:1-8.Baggs, G.; Seth, A.; Oliver, J. S.; Jones, W. M.; liu, L.; Toth, S. M. (2008): Monitoring Clinical Trial Data Using an Unblinded Industry Statistician. In: Drug Information Journal 42, S. 193–199. Online verfügbar unter doi:10.1177/009286150804200211.
Baigent, Colin; Harrell, Frank E.; Buyse, Marc; Emberson, Jonathan R.; Altman, Douglas G. (2008): Ensuring trial validity by data quality assurance and diversification of monitoring methods. In: Clinical trials (London, England) 5 (1), S. 49–55. DOI: 10.1177/1740774507087554.
Bakobaki, Julie M.; Rauchenberger, Mary; Joffe, Nicola; McCormack, Sheena; Stenning, Sally; Meredith, Sarah (2012): The potential for central monitoring techniques to replace on-site monitoring: findings from an international multi-centre clinical trial. In: Clinical trials (London, England) 9 (2), S. 257–264. DOI: 10.1177/1740774511427325.
Bertoye, P. H., S. Courcier-Duplantier, et al. Adaptation of the application of good clinical practice depending on the features of specific research projects. Therapie 2006; 61(4): 279-85, 271-7.
Brosteanu, Oana; Houben, Peggy; Ihrig, Kristina; Ohmann, Christian; Paulus, Ursula; Pfistner, Beate et al. (2009): Risk analysis and risk adapted on-site monitoring in noncommercial clinical trials. In: Clinical trials (London, England) 6 (6), S. 585–596. DOI: 10.1177/1740774509347398.
Buyse, M.; George, S. L.; Evans, S.; Geller, N. L.; Ranstam, J.; Scherrer, B. et al. (1999): The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials. In: Statistics in medicine 18 (24), S. 3435–3451.
Buyse M (2014): Centralized Statistical Monitoring As a Way to Improve the Quality of Clinical Data. In: Applied Clinical Trials. Online verfügbar unter http://www.appliedclinicaltrialsonline.com/centralized-statistical-monitoring-way-improve-quality-clinical-data?pageID=1.
Clinical Trials Transformation Initiative. https://www.ctti-clinicaltrials.org/
Cooley S, S. B. Triggered monitoring. Applied clinical trials online.2010
DAMOCLES (2005): A proposed charter for clinical trial data monitoring committees: helping them to do their job well. Helping them to do their job well. In: Lancet (London, England) 365 (9460), S. 711–722. DOI: 10.1016/S0140-6736(05)17965-3.
De, S. Hybrid approaches to clinical trial monitoring: Practical alternatives to 100% source data verification. Sheetz, N.; Wilson, B.; Benedict, J.; Huffman, E.; Lawton, A.; Travers, M. et al. (2014): Evaluating Source Data Verification as a Quality Control Measure in Clinical Trials. In: Therapeutic Innovation & Regulatory Science 48 (6), S. 671–680. DOI: 10.1177/2168479014554400.
Desmet, L.; Venet, D.; Doffagne, E.; Timmermans, C.; Burzykowski, T.; Legrand, C.; Buyse, M. (2014): Linear mixed-effects models for central statistical monitoring of multicenter clinical trials. In: Statistics in medicine 33 (30), S. 5265–5279. DOI: 10.1002/sim.6294.
Djali, S.; Janssens, S.; van Yper, S.; van Parijs, J. (2010): How a Data-Driven Quality Management System Can Manage Compliance Risk in Clinical Trials. In: Drug Information Journal 44, S. 359–373.
Edwards, Phil; Shakur, Haleema; Barnetson, Lin; Prieto, David; Evans, Stephen; Roberts, Ian (2013): Central and statistical data monitoring in the Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage (CRASH-2) trial. In: Clinical trials (London, England) 11 (3), S. 336–343. DOI: 10.1177/1740774513514145.
European Commission. Enterprise and Industry Directorate-General. Draft guidance on ‘specific modalities’ for non-commercial clinical trials referred to in Commission Directive 2005/28/EC laying down the principles and detailed guidelines for good clinical practice.http://ec.europa.eu/health/files/pharmacos/docs/doc2006/07_2006/guide_noncommercial_2006_07_27_en.pdf
European Medicines Agency (2002). Note for Guidance on Good Clinical Practice.http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf.
European Medicines Agency (2013): Reflection paper on risk-based quality management in clinical trials. Online verfügbar unterhttp://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/11/WC500155491.pdf, Accessed 06.10.2015.
Food and Drug Administration. Guidance for Industry Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring.
Graham, L., S. Anwar, et al. Risk management of non-CTIMP trials: Focus on complex intervention trials. Clinical Trials 2012; 9(4): 517.
Grieve, A. P. (2012): Source Data Verification by Statistical Sampling. Issues in Implementation. In: Drug Information Journal 46 (3), S. 368–377. DOI: 10.1177/0092861512442057.
Guthrie, Lauren B.; Oken, Emily; Sterne, Jonathan A. C.; Gillman, Matthew W.; Patel, Rita; Vilchuck, Konstantin et al. (2012): Ongoing monitoring of data clustering in multicenter studies. In: BMC medical research methodology 12, S. 29. DOI: 10.1186/1471-2288-12-29.
Heels-Ansdell, D., S. Walter, et al. Central statistical monitoring of an international thromboprophylaxis trial. American Journal of Respiratory and Critical Care Medicine 2010; 181(1).
Henderson, L. (2013): Distinct RBM Divisions: source document verification and source data review. In: Applied Clinical Trials July.
Hughes, Sara; Harris, Julia; Flack, Nancy; Cuffe, Robert L. (2012): The statistician's role in the prevention of missing data. In: Pharmaceutical statistics 11 (5), S. 410–416. DOI: 10.1002/pst.1528.
Journot V, Pignon JP, Gaultier C, et al. On behalf of the Optimon Collaborative Group. Validation of a risk assessment scale and a risk-adapted monitoring plan for academic clinical research studies – The Pre-Opti¬mon
Journot, Valérie; Pérusat-Villetorte, Sophie; Bouyssou, Caroline; Couffin-Cadiergues, Sandrine; Tall, Aminata; Chêne, Geneviève (2013): Remote pre enrollment checking of consent forms to reduce nonconformity. In: Clinical trials (London, England) 10 (3), S. 449–459. DOI: 10.1177/1740774513480003.
Kendall, Brigitte; Städeli, Reto; Schegg, Belinda; Olbrich, Martin; Chen, Edmond; Harmelin-Kadouri, Rona et al. (2012): Clinical Trial Educator program - a novel approach to accelerate enrollment in a phase III International Acute Coronary Syndrome Trial. In: Clinical trials (London, England) 9 (3), S. 358–366. DOI: 10.1177/1740774512440760.
Kirkwood, Amy A.; Cox, Trevor; Hackshaw, Allan (2013): Application of methods for central statistical monitoring in clinical trials. In: Clinical trials (London, England) 10 (5), S. 783–806. DOI: 10.1177/1740774513494504.
Kirwan, Bridget-Anne; Lubsen, Jacobus; Brouwer, Sophie de; van Dalen, Frederik J.; Pocock, Stuart J.; Clayton, Tim et al. (2008): Quality management of a large randomized double-blind multi-centre trial: the ACTION experience. In:Contemporary clinical trials 29 (2), S. 259–269. DOI: 10.1016/j.cct.2007.10.001.
Lane, J. Athene; Wade, Julia; Down, Liz; Bonnington, Susan; Holding, Peter N.; Lennon, Teresa et al. (2011): A Peer Review Intervention for Monitoring and Evaluating sites (PRIME) that improved randomized controlled trial conduct and performance. In: Journal of clinical epidemiology 64 (6), S. 628–636. DOI: 10.1016/j.jclinepi.2010.10.003.
Lindblad, Anne S.; Manukyan, Zorayr; Purohit-Sheth, Tejashri; Gensler, Gary; Okwesili, Paul; Meeker-O'Connell, Ann et al. (2014): Central site monitoring: results from a test of accuracy in identifying trials and sites failing Food and Drug Administration inspection. In: Clinical trials (London, England) 11 (2), S. 205–217. DOI: 10.1177/1740774513508028.
Macefield, R. C., A. D. Beswick, et al. A systematic review of on-site monitoring methods for health-care randomised controlled trials. Clin Trials 2013; 10(1): 104-24.Mealer, Meredith; Kittelson, John; Thompson, B. Taylor; Wheeler, Arthur P.; Magee, John C.; Sokol, Ronald J. et al. (2013): Remote source document verification in two national clinical trials networks: a pilot study. In: PloS one 8 (12), S. e81890. DOI: 10.1371/journal.pone.0081890.
McBee, W. L., S. Schenning, et al. Effective monitoring strategies in a long-term clinical trial with varying levels of clinic staff knowledge: The AREDS2 experience. Clin Trials 2012; 9(4): 462.
Méthot J, Brisson D, Gaudet D. On-site management of investigational products and drug delivery systems in conformity with Good Clinical Practices (GCPs). Clin Trials 2012; DOI: 10.1177/1740774511431280
Mitchel, J. T.; Kim, Y. J.; Choi J; Park, G.; Cappi, S.; Horn, D. et al. (2011): Evaluation of Data Entry Errors and Data Changes to an Electronic Data Capture Clinical Trial Database. In: Drug Information Journal 45, S. 421–430.
Morrison, B., J. Neaton, et al. A CTTI survey of current monitoring practices. Clinical Trials 2010; 7(4): 464.
Morrison BW, Cochran CJ, White JG. Monitoring the quality of conduct of clinical trials: a survey of current practices. Clin Trials 2011; 8: 342-9
MRC/DH Joint project to codify good practice in publicly-funded UK clinical trials with medicines http://www.ct-toolkit.ac.uk
MRC/DH/MHRA Joint Project. Risk-adapted Approaches to the Management of Clinical Trials of Investigational Medicinal Products (Version: 10th October 2011) http://www.mhra.gov.uk/home/groups/l-ctu/documents/websiteresources/con111784.pdf
Nielsen, E.; Hyder, D.; Deng, C. (2014): A Data-Driven Approach to Risk-Based Source Data Verification. In: Therapeutic Innovation & Regulatory Science 48 (2), S. 173–180. DOI: 10.1177/2168479013496245.
Novik, Y., L. Fleming, et al. Monitoring data and compliance in institutional cancer trials: Consistent quality improvement by internal peer audit process. Clinical Trials 2010; 7(4): 430.
Pocock, Stuart J. (2006): Current controversies in data monitoring for clinical trials. In: Clinical trials (London, England) 3 (6), S. 513–521. DOI: 10.1177/1740774506073467.
Pogue, Janice M.; Devereaux, P. J.; Thorlund, Kristian; Yusuf, Salim (2013): Central statistical monitoring: detecting fraud in clinical trials. In: Clinical trials (London, England) 10 (2), S. 225–235. DOI: 10.1177/1740774512469312.
Sandman L, Mosher A, Khan A. Quality assurance in a large clinical trials consortium: The experience of the Tuberculosis Trials Consortium. Contemp Clin Trials 2006; (27): 554–560
Shugarts, P., R. Kozloff, et al. Risk-based approach to monitoring: The way of the future. Clinical Trials 2012; 9(4): 462.Grant, A.; Altman, D.; Babiker, A.; Campbell, M.; Clemens, F.; Darbyshire, J. et al. (2005): Issues in data monitoring and interim analysis of trials. In: Health Technol Assess 9 (7). DOI: 10.3310/hta9070.
Tantsyura, V.; Dunn, I. M.; Fendt, K.; Kim, Y. J.; Waters, J.; Mitchel, J. (2015a): Risk-Based Monitoring. A Closer Statistical Look at Source Document Verification, Queries, Study Size Effects, and Data Quality. In: Therapeutic Innovation & Regulatory Science. DOI: 10.1177/2168479015586001.
Tantsyura, V.; Dunn, I. M.; Waters, J.; Fendt, K.; Kim, Y. J.; Viola, D.; Mitchel, J. (2015b): Extended Risk-Based Monitoring Model, On-Demand Query-Driven Source Data Verification, and Their Economic Impact on Clinical Trial Operations. In:Therapeutic Innovation & Regulatory Science. DOI: 10.1177/2168479015596020.
Tantsyura, Vadim; Grimes, Imogene; Mitchel, Jules; Fendt, Kaye; Sirichenko, Sergiy; Waters, Joel et al. (2010): Risk-Based Source Data Verification Approaches: Pros and Cons. In: Drug Information Journal 44, S. 745–756. Online verfügbar unter doi:10.1177/009286151004400611.
Taylor, R.; McEntegart, D.; Stillman, E. (2002): Statistical techniques to detect fraud and other data irregularities in clinical questionnaire data. In: Drug Information Journal 36, S. 115–125.
Timmermans, Catherine; Doffagne, Erik; Venet, David; Desmet, Lieven; Legrand, Catherine; Burzykowski, Tomasz; Buyse, Marc (2015a): Statistical monitoring of data quality and consistency in the Stomach Cancer Adjuvant Multi-institutional Trial Group Trial. In: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. DOI: 10.1007/s10120-015-0533-9.
Timmermans, Catherine; Venet, David; Burzykowski, Tomasz (2015b): Data-driven risk identification in phase III clinical trials using central statistical monitoring. In: International journal of clinical oncology. DOI: 10.1007/s10147-015-0877-5.
TransCelerate BioPharma Inc (2013): TransCelerate-RBM-Position-Paper-FINAL-30MAY2013. Online verfügbar unter http://www.transceleratebiopharmainc.com/, zuletzt geprüft am 08.10.2015.
Tudur Smith, Catrin; Stocken, Deborah D.; Dunn, Janet; Cox, Trevor; Ghaneh, Paula; Cunningham, David; Neoptolemos, John P. (2012): The value of source data verification in a cancer clinical trial. In: PloS one 7 (12), S. e51623. DOI: 10.1371/journal.pone.0051623.
Tudur Smith C, Williamson P, Jones A, Smyth A, Langton Hewer S, Gamble C (2014): Risk-proportionate clinical trial monitoring: an example approach from a non-commercial trials unit. In: Trials 15, S. 127. DOI: 10.1186/1745-6215-15-127.
US Food and Drug Administration (2013): Guidance for Industry Oversight of Clinical Investigations — A Risk- Based Approach to Monitoring. Online verfügbar, zuletzt geprüft am 06.10.2015.
Venet D, Doffagne E, Burzykowski T, Beckers F, Tellier Y, Genevois-Marlin E et al. (2012): A statistical approach to central monitoring of data quality in clinical trials. In: Clinical trials (London, England) 9 (6), S. 705–713. DOI: 10.1177/1740774512447898.
Williams GW. The other side of clinical trial monitoring; assuring data quality and procedural adherence. Clin Trials 2006 3: 530-7
Wilson, B.; Provencher, T.; Gough, J.; Clark, S.; Abdrachitov, R.; Roeck, K. de et al. (2014): Defining a Central Monitoring Capability. Sharing the Experience of TransCelerate BioPharma's Approach, Part 1. In: Therapeutic Innovation & Regulatory Science 48 (5), S. 529–535. DOI: 10.1177/2168479014546335.
Wu, Xiaoru; Carlsson, Martin (2011): Detecting data fabrication in clinical trials from cluster analysis perspective. In: Pharmaceutical statistics 10 (3), S. 257–264. DOI: 10.1002/pst.462.